文献速递外周动脉疾病

股腘旁路术后当代(2009-2014)临床结局劣于BASIL试验(1999-2004)报告

Contemporary (2009-2014) clinical outcomes after femoropopliteal bypass surgery for chronic limb threatening ischemia are inferior to those reported in the UK Bypass versus Angioplasty for Severe Ischaemia of the Leg (BASIL) trial (1999-2004).
PubMed 文献 · J Vasc Surg · 2019-03-07

该研究比较了BASIL试验(1999-2004)中128例与当代系列(2009-2014)中50例因慢性肢体威胁性缺血行股腘旁路术患者的结局。尽管当代组30天并发症和死亡率更低,但无截肢生存率、保肢率、总生存率和主要不良肢体事件均显著更差。

要点

  • 当代股腘旁路术后长期结局显著劣于BASIL试验。
  • 当代组30天并发症和死亡率更低,但长期结局更差。
  • 需进一步研究确认当代数据是否可推广并探究原因。

核心结论

  • 当代系列股腘旁路术后所有考察的长期临床结局均显著劣于BASIL-1试验。

研究设计与样本

  • 回顾性比较研究,BASIL-1组128例(1999-2004),当代系列组50例(2009-2014),均因CLTI行股腘旁路术。

主要发现

  • BASIL-1组与当代组30天并发症和死亡率分别为45.3% vs 22%(P = .004)。
  • 无截肢生存率BASIL-1组62% vs 当代组28%(HR 1.86;95%CI 1.18-2.93;P = .007)。
  • 保肢率BASIL-1组85% vs 当代组69%(HR 2.31;95%CI 1.14-4.68;P = .02)。
  • 总生存率BASIL-1组69% vs 当代组35%(HR 1.66;95%CI 1.00-2.74;P = .05)。
  • 主要不良肢体事件BASIL-1组67% vs 当代组47%(HR 1.93;95%CI 1.15-3.22;P = .01)。

临床怎么用

  • 临床应关注当代股腘旁路术后长期结局劣于既往试验的现象,审慎评估旁路手术决策。

局限性

  • 当代系列为单中心回顾性数据,样本量较小(50例),可能限制结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bypass surgery (BS) remains the gold standard revascularization strategy in patients with chronic limb-threatening ischemia (CLTI) owing to infrainguinal disease. The Bypass versus Angioplasty for Severe Ischaemia of the Leg (BASIL)-1 trial showed that, in patients with CLTI who survived for 2 years or more, BS resulted in better clinical outcomes. Despite this finding, there has been an increasing trend toward an endovascular-first approach to infrainguinal CLTI. Our aim was to investigate whether changes in practice have impacted the clinical outcomes of BS in our unit 10 years after BASIL-1. METHODS: Data for patients who underwent femoropopliteal (FP) BS in BASIL-1 (1999-2004) were retrieved from trial case record forms. The comparator contemporary series (CS) comprised all patients undergoing FP BS for CLTI in our unit between 2009 and 2014. Demographic and clinical outcome data on patients in the CS were collected from the prospectively collected hospital electronic notes. Anatomic patterns of disease in the BASIL-1 and CS cohorts were scored using the Bollinger and GLASS criteria. Statistical analysis was performed in SAS v9.4. RESULTS: There were 128 patients from BASIL-1 and 50 patients in the CS. Baseline age, gender, affected limb, and diabetes prevalence were similar, as were days spent in hospital out to 12 months and length of follow-up. BASIL-1 patients were more likely to be current smokers (P = .000) and had a higher creatinine (P = .04). The 30-day morbidity and mortality were higher in BASIL-1 (45.3% vs 22%; P = .004). There was no significant difference between BASIL-1 and CS with regard to run-off Bollinger (37.7 vs 32.1; P = .167) and IP GLASS (0 vs 0; P = .390) scores, with both groups having a median of two runoff vessels. Amputation-free survival (62% vs 28%; hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.18-2.93; P = .007), limb salvage (85% vs 69%; HR, 2.31; 95% CI, 1.14-4.68; P = .02), overall survival (69% vs 35%; HR, 1.66; 95% CI, 1.00-2.74; P = .05) and major adverse limb events (67% vs 47%; HR, 1.93; 95% CI, 1.15-3.22; P = .01) were all significantly better in BASIL-1. CONCLUSIONS: Although 30-day mortality and morbidity were significantly lower, all of the examined longer term clinical outcomes after FP BS were significantly worse in the CS group a decade on from BASIL-1. Further research in the form of prospective cohort studies and randomized controlled trials is urgently required to determine if the CS data reported herein are generalizable to current vascular surgical practice and, if so, to determine the reasons for these unexpected outcomes.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Meecham L, Popplewell M, Bate G, et al. Contemporary (2009-2014) clinical outcomes after femoropopliteal bypass surgery for chronic limb threatening ischemia are inferior to those reported in the UK Bypass versus Angioplasty for Severe Ischaemia of the Leg (BASIL) trial (1999-2004). J Vasc Surg. 2019. PMID: 30852037. doi:10.1016/j.jvs.2018.08.197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。